Company intelligence / Profile preview

Allon Therapeutics Inc.

Vancouver, British Columbia, Canadaorpha.net ↗

Ownership: Private
Development stage: Phase 3

Overview

Demonstrated statistically significant efficacy in Phase II clinical trials for amnestic mild cognitive impairment, showing 62.4% improvement in delayed-match-to-sample test and 17.2% increase in digit span test with high dose treatment. Received Orphan Drug Designation from FDA for davunetide in progressive supranuclear palsy.

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculesNeuroprotective peptides
Industry: Biotech

Drug pipeline

1 asset

davunetide

Phase 3

Indications: Progressive supranuclear palsy, Cognitive impairment, Schizophrenia, Alzheimer disease

Partnerships

Nordic Biotech Venture Fund II K/S

Beyond the preview

Go deeper on Allon Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allon Therapeutics Inc..

Explore the full profile